Shares of Exelixis, Inc. (NASDAQ:EXEL) have been given an average rating of “Buy” by the fifteen research firms that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $29.44.

Several brokerages have weighed in on EXEL. Oppenheimer set a $40.00 price objective on Exelixis and gave the company a “buy” rating in a research note on Thursday. BidaskClub upgraded Exelixis from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 6th. Piper Jaffray Companies dropped their price objective on Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 5th. Guggenheim began coverage on Exelixis in a research note on Monday, September 17th. They set a “buy” rating on the stock. Finally, Goldman Sachs Group began coverage on Exelixis in a research note on Monday, September 17th. They set a “neutral” rating and a $22.00 price objective on the stock.

In other news, insider Michael Morrissey sold 25,000 shares of Exelixis stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $17.22, for a total transaction of $430,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Patrick J. Haley sold 20,000 shares of Exelixis stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $17.32, for a total value of $346,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 216,500 shares of company stock worth $3,692,860 over the last quarter. Company insiders own 4.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its holdings in Exelixis by 31.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 17,220 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 4,095 shares during the last quarter. American Century Companies Inc. increased its holdings in Exelixis by 504.6% in the 2nd quarter. American Century Companies Inc. now owns 2,034,270 shares of the biotechnology company’s stock worth $43,777,000 after acquiring an additional 1,697,822 shares during the last quarter. First Trust Advisors LP increased its holdings in Exelixis by 78.6% in the 3rd quarter. First Trust Advisors LP now owns 4,643,726 shares of the biotechnology company’s stock worth $82,287,000 after acquiring an additional 2,044,201 shares during the last quarter. Retirement Systems of Alabama purchased a new stake in Exelixis in the 2nd quarter worth about $7,692,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in Exelixis by 4.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,019,297 shares of the biotechnology company’s stock worth $21,936,000 after acquiring an additional 47,730 shares during the last quarter. Institutional investors own 79.37% of the company’s stock.

Shares of NASDAQ:EXEL opened at $17.92 on Monday. The company has a current ratio of 8.66, a quick ratio of 8.54 and a debt-to-equity ratio of 0.01. Exelixis has a 1-year low of $13.42 and a 1-year high of $32.20. The firm has a market cap of $5.36 billion, a price-to-earnings ratio of 15.19, a P/E/G ratio of 1.06 and a beta of 2.29.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $174.14 million. During the same period last year, the business earned $0.26 EPS. The business’s revenue was up 47.8% on a year-over-year basis. As a group, sell-side analysts forecast that Exelixis will post 1.3 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: Understanding the different types of bonds

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.